Introduction
============

The evaluation of germline mutations in high-penetrance epithelial ovarian cancer (EOC) predisposition genes, specifically *BRCA1* and *BRCA2* (*BRCA1/2*), has become a standard clinical practice. Lifetime estimates of EOC risk range from 24% to 59% and 8% to 35% in *BRCA1* and *BRCA2* carriers, respectively \[[@b1-crt-2017-220]-[@b4-crt-2017-220]\]. Identification of *BRCA1/2* mutations allows the application of preventive strategies, including breast magnetic resonance imaging (MRI) screening or risk-reducing surgeries, which can improve survival \[[@b5-crt-2017-220],[@b6-crt-2017-220]\].

With the advances in the next-generation sequencing (NGS), simultaneous sequencing of multiple cancer susceptibility genes beyond *BRCA* has become available through multi-gene panel testing in a less expensive and more rapid manner, compared with that of the single-gene testing \[[@b7-crt-2017-220]\]. Additionally, testing multiple genes simultaneously creates the potential for unexpected findings as well as for the identification of genetic alterations for which the clinical management has not been established yet \[[@b7-crt-2017-220]-[@b9-crt-2017-220]\]. Previous investigations of germline mutations using multi-gene panel testing of EOC patients revealed that 18%-24% of patients carry germline mutations in *BRCA1/2*, *BARD1*, *BRIP1*, *CHEK2*, *MRE11A*, *MSH6*, *NBN*, *PALB2*, *RAD50*, *RAD51C*, *RAD51D*, or *TP53* genes \[[@b7-crt-2017-220],[@b9-crt-2017-220]\]. Furthermore, in one study, which included 127 EOC patients who previously underwent noninformative genetic screening, nine patients (7%) were found to have pathogenic mutations in *APC*, *ATM*, *BRCA2*, *BRIP1*, *MUTYH*, and *RAD51D* genes \[[@b8-crt-2017-220]\].

However, considering the ethnicity-specific differences in the germline mutations in cancer susceptibility genes, the assessment of cancer susceptibility gene variants in all ethnic groups using clinical data is necessary. In Asians, no previous studies evaluated the frequency of germline mutations in cancer susceptibility genes other than *BRCA1/2* genes in individuals with EOC who were referred for genetic evaluation.

The primary objective of this study was to investigate the frequency and spectrum of germline mutations in 35 cancer susceptibility genes using multi-gene panel testing in a population of consecutive Korean patients with EOC.

Materials and Methods
=====================

1. Patient selection
--------------------

All women with EOC admitted to Severance Hospital, Yonsei University, South Korea, between March 2016 and December 2016, who consented to multi-gene panel testing for clinical research, were included in this study. Blood samples of the participants were obtained, and the clinical and pathologic data abstracted from medical records included personal and family cancer histories, cancer histology, stage, ancestry, and previous genetic test results. All ovarian cancers were reviewed by a gynecologic pathologist panel at the same institute. Genetic test results obtained in this study were considered research results and were not returned to study participants or utilized for clinical decision making.

2. NGS assay
------------

Germline DNA was extracted from peripheral blood sample of the participants using the QIAamp Blood DNA mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Intact DNA was quantified and adjusted to the concentration of 5 ng/μL using a Qubit 2.0 Fluorometer (Invitrogen, Waltham, MA) and the Qubit dsDNA HS Assay Kit (Invitrogen). Precapture libraries were constructed according to the manufacturer's sample preparation protocol. Genomic DNA of each patient was fragmented to a median size of 300 bp. We used customized targeted capture sequencing panel (OncoRisk, Celemics, Seoul, Korea) covering all coding sequences and intron-exon boundaries of the coding exons of 35 cancer susceptibility genes, including *BRCA1*, *BRCA2*, *PALB2*, *BARD1*, *BRIP1*, *RAD51C*, *RAD51D*, *RAD50*, *NBN*, *MRE11A*, *ATM*, *CHEK2*, *TP53*, *PTEN*, *APC*, *BLM*, *BMPR1A*, *CDH1*, *CDK4*, *CDKN2A*, *EPCAM*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *PMS2*, *POLE*, *PRSS1*, *RET*, *SLX4*, *SMAD4*, *STK11*, *VLH*, and *WT1*. DNA fragments were end-repaired, phosphorylated, and adenylated at the 3′ ends. The index adaptors were ligated to the repaired ends, DNA fragments were amplified, and fragments of 200 to 500 bp were isolated. Pooled libraries were sequenced on a MiSeq sequencer (Illumina, San Diego, CA) using the MiSeq Reagent Kit v2 (300 cycles).

3. NGS data analysis
--------------------

All clinically actionable variants identified by NGS, as well as regions that did not meet our preset NGS quality metrics, were independently confirmed with orthogonal site-specific Sanger sequencing. Analyzed genes were categorized according to the cancer type-predisposing mutations ([Table 1](#t1-crt-2017-220){ref-type="table"}).

4. Annotation and variant classification
----------------------------------------

Variants were described according to nomenclature recommendations of the Human Genome Variation Society (<http://www.hgvs.org/mutnomen>) and further categorized according to the American College of Medical Genetics and Genomics recommendations, with supporting linkage, biochemical, clinical, functional, and statistical data used for specific missense and intronic alterations \[[@b10-crt-2017-220]-[@b12-crt-2017-220]\]. The variants were classified into pathogenic, likely pathogenic, variant of uncertain significance (VOUS), likely benign, and benign/polymorphism, using five-tier system following the guidelines of the American College of Medical Genetics and Genomics \[[@b10-crt-2017-220]\]. Initially, variants were filtered by their frequencies in population control databases including ExAC (non‒The Cancer Genome Atlas dataset; frequencies were calculated according to the ethnic subgroups), ESP6500, 1000 Genomes Project, and Korean Reference Genome Database. Variants with a minor allele frequency (MAF) greater than 5% in any of the population subgroups were classified as absolutely benign. Conventionally, variants with a MAF greater than 0.5% were considered as having a strong evidence for a benign variant, whereas the evidence supporting pathogenicity was considered moderate if these variants were shown to be absent from the general population. Furthermore, literature and database search for previous reports and functional studies was performed using Alamut Visual 2.6 software (Interactive Biosoftware, Rouen, France) and Human Gene Mutation Database professional database. When all in silico analyses showed consistent predictions, the results were considered the evidence demonstrating that a certain variant is benign or pathogenic.

5. Confirmation by other methods
--------------------------------

We identified all small base pair variations using Sanger sequencing on a 3730 DNA Analyzer with the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA). Sequencing data were aligned against appropriate reference sequences and analyzed using the Sequencher 5.3 software (Gene Codes Corp., Ann Arbor, MI). Chromosomal copy number alterations were confirmed using the Infinium CytoSNP 850K array (Illumina) and BlueFuse Multi software (Illumina).

6. Ethical statement
--------------------

This study was approved by the Institutional Review Board of the Yonsei University College of Medicine (No. 4-2015-0141) and performed in accordance with the ethical standards described in the Declaration of Helsinki. The requirement to obtain a written informed consent was waived by the Institutional Review Board of the Yonsei University College of Medicine because our study was retrospective research based on medical records, and this research presented no more than minimal risk of harm to subjects.

Results
=======

1. Study population
-------------------

In [Fig. 1](#f1-crt-2017-220){ref-type="fig"}, the results of multi-gene panel testing are presented. Of 117 patients with EOC, 44 deleterious mutations were identified in 38 (32.5%) women, and 55 patients (47.0%) were revealed to carry only VOUSs in 34 genes. Multiple genetic mutations were concomitantly identified in a patient. Clinical and tumor pathologic features of study participants per state of mutation are shown in [Table 2](#t2-crt-2017-220){ref-type="table"}. Out of 38 patients with pathogenic or likely pathogenic mutations, 31 had *BRCA1/2* mutation and eight were shown to carry non-*BRCA1/2* mutations. All the *BRCA1/2* mutations detected in NGS assay were also confirmed by Sanger sequencing. The median age at diagnosis was 52 years (range, 16 to 83 years); 99.1% of the study population was Asian, and 0.9% was non-Ashkenazi white; 71.8% of the patients had stage III or IV disease. Furthermore, 54.7% of patients reported having a first-degree relative with cancer. In total, 64 patients (54.7%) had a family history of cancer, and among 38 patients who carried deleterious mutations in genes, 25 patients (65.8%) had family history of cancer in first-degree relatives. Concurrent breast cancers were found in seven patients (6%), and five of them carried *BRCA1* mutation, while one carried *BRCA2*. There were no significant differences in the clinicopathologic characteristics between patients with *BRCA1/2* mutation and patients with non-*BRCA1/2* mutation. Also, Kaplan-Meier analysis showed there were no differences in progression-free survival (p=0.567) and overall survival (p=0.492) between the two groups ([S1 Fig.](#SD1-crt-2017-220){ref-type="supplementary-material"})

2. Frequency and spectrum of pathogenic and likely pathogenic mutations
-----------------------------------------------------------------------

Frequency of genetic alterations, including pathogenic or likely pathogenic mutations and VOUSs, is illustrated in [Fig. 2](#f2-crt-2017-220){ref-type="fig"}. All the data with anonymized and deidentified patient information is available in [S2 Table](#SD2-crt-2017-220){ref-type="supplementary-material"}. Among 117 patients with EOC, 39 pathogenic or likely pathogenic mutations were identified in 38 women (32.5%). Out of 39 germline mutations detected, 31 (79.5%) were shown to be germline *BRCA1/2* mutation, 21 in *BRCA1*, and 10 in *BRCA2*. In addition, eight (6.8%) women had a total of eight deleterious mutations in non-*BRCA1/2* cancer predisposition genes including *BRIP1* (n=1), *CHEK2* (n=1), *MSH2* (n=1), *POLE* (n=1), *RAD51C* (n=2), and *RAD51D* (n=2). Characteristics of patients with non-*BRCA1/2* mutations are presented in [Table 3](#t3-crt-2017-220){ref-type="table"}.

We did not find any deleterious mutations in *APC*, *ATM*, *BARD1*, *BLM*, *BMPR1A*, *BMPR1B*, *CDH1*, *CDH2*, *CDKN2A*, *EPCAM*, *MEN1*, *MRE11A*, *MLH1*, *MSH6 MUTYH*, *NBN*, *PALB2*, *PMS2*, *PRSS1*, *RAD50*, *RET*, *SLX4*, *STK11*, *TP53*, *VHL*, or *WT1* genes.

3. Frequency of VOUSs in cancer susceptibility genes
----------------------------------------------------

Clinical and tumor pathologic features of study participants per state of VOUS are presented in [S3 Table](#SD1-crt-2017-220){ref-type="supplementary-material"}. Frequency and spectrum of identified VOUSs are illustrated in [Fig. 3](#f3-crt-2017-220){ref-type="fig"}. At least one VOUS was identified in 78 women (66.7%), and 145 VOUSs have been identified in total. Twenty-five patients with VOUS also had a concomitant deleterious mutation. Among 54 patients (46.2%) that carried only VOUSs, 30 patients had a family history of cancer in the first-degree relatives.

Discussion
==========

To the best of our knowledge, this is the first study that included consecutively enrolled EOC patients of the Asian ethnicity, and retrospectively examined the frequency and spectrum of germline mutations in *BRCA1/2* and other cancer predisposition genes. Among 117 patients, we found that 38 patients (32.5%) carried pathogenic and likely pathogenic mutations, while eight patients (6.8%) were shown to have mutations in non-*BRCA1/2* cancer predisposition genes, including *BRIP1*, *CHEK2*, *MSH2*, *POLE*, *RAD51C*, and *RAD51D*.

A large-scale study presented spectrum of germline mutations of ovarian cancer patients, whose ethnicities were predominantly non-Hispanic whites (87.4%) \[[@b9-crt-2017-220]\]. The research reported germline mutations in *BRIP1* (1.4%), *RAD51C* (0.6%), *RAD51D* (0.6%), *MLH1* (0.01%), and *CHEK2* (0.06%), which also found in our study. \[[@b9-crt-2017-220]\] However, considering the extensive gap between the numbers of subjects (1,915 patients vs. 117 patients), a direct comparison with our results is not acceptable. NGS panel test for patients with EOC began to be covered by National Health Insurance from March 2017, systematic gathering and analysis of the produced data from ovarian cancer patients with Korean ethnicity are required to compare with the data from another ethnicity.

*RAD51C* and *RAD51D* are known to correlate with an increased risk of EOC due to their involvement in the Fanconi-BRCA pathway \[[@b13-crt-2017-220],[@b14-crt-2017-220]\]. *RAD51C* mutations are found in 1% of unselected EOC patients and confer an overall lifetime EOC risk of about 9% at an average onset age of 60 years \[[@b14-crt-2017-220]\]. A previous population-based case-control study demonstrated that *RAD51C* and *RAD51D* represent moderate EOC susceptibility genes, and 18% of EOCs (more frequently in high-grade serous type) carrying *RAD51C* and *RAD51D* mutations developed at age 50 or younger. If this risk estimate is confirmed, risk-reducing salpingo-oophorectomy may be a beneficial option for premenopausal women \[[@b15-crt-2017-220]\]. We identified four participants with pathogenic or likely pathogenic mutations, including *RAD51C* c.597_603delCACTCTT (p.Phe199LeufsTer38), *RAD51D* c.270_271dupTA (p.Lys91IlefsTer13), and *RAD51D* c.904-2A\>T.

BRCA1-interacting protein C-terminal helicase 1 (*BRIP1*) is involved in the BRCA-Fanconi anemia pathways, and it was identified as a moderate-penetrance gene, conferring an increased risk for EOC, with 6-8-fold increased EOC risk and 10%-15% lifetime risk \[[@b16-crt-2017-220],[@b17-crt-2017-220]\]. Another report demonstrated that *BRIP1* mutations were found in 1.4% of EOC patients, and they were shown to be associated with a moderate increase in EOC risk. These data have clinical implications for the development of preventive strategies for the *BRIP1* mutation carriers \[[@b18-crt-2017-220]\]. We identified one patient in our study as a carrier of a deleterious mutation, *BRIP1* c.1776G\>A (p.Trp592Ter), who has no family history of cancer in the first-degree relatives.

Cell-cycle checkpoint kinase 2 (*CHEK2*) plays a role in cell-cycle arrest and DNA repair and its mutations contribute to the development of hereditary and sporadic cancers \[[@b19-crt-2017-220]\]. One meta-analysis showed that *CHEK2* 1100delC increases the lifetime risk 3-5 folds, with a 37% increase in the cumulative risk of breast cancer by the age of 70 \[[@b20-crt-2017-220]\]. A previous study examining Asian population reported that *CHEK2* c.1111C\>T (p.His371Tyr, rs531398630) was detected in familial and unselected breast cancer cases and controls, with 4.24% (5/118), 1.76% (16/909), and 0.73% (9/1228), respectively \[[@b21-crt-2017-220]\]. In this study, we identified two EOC patients (age, 31 and 40 years) with pathogenic mutation, *CHEK2* c.1111C\>T (p.His371Tyr) and c.1555C\>T (p.Arg519Ter), and a family history of hematologic cancer and colon cancer in the first-degree relatives, respectively. The patients were referred to the department of breast surgery, and followed up with regular surveillance using breast MRI.

The benefit of genetic testing for *BRCA1/2* mutations is well established. In addition to cancer prevention strategies such as risk-reducing surgery, *BRCA*-associated cancers were confirmed to show a better response to therapies such as poly(ADP) ribose polymerase (PARP) inhibitors and platinum agents than sporadic cancers \[[@b22-crt-2017-220],[@b23-crt-2017-220]\]. Considering the role of *BRIP1*, *CHEK2*, *RAD51C*, and *RAD51D* in the *BRCA* pathway responsible for DNA repair, EOCs in patients with mutations in *BRIP1*, *CHEK2*, *RAD51C*, or *RAD51D* may represent potential targets for PARP1 inhibitors, similar to the *BRCA1/2* mutation carriers.

The usefulness of multi-gene panel testing aimed at the detection of germline mutations would be more beneficial for the familial surveillance and risk-reduction strategies, rather than the application of a targeted therapy, such as PARP1 inhibition therapy. Currently, the National Comprehensive Cancer Network (NCCN) guidelines recommend risk-reducing salpingo-oophorectomy when known mutations in the EOC-associated genes (*BRCA1*, *BRCA2*, *RAD51C*, *RAD51D*, *BRIP1*, *MSH2*, *MLH1*, *MSH6*, and *PMS2*) are detected \[[@b24-crt-2017-220]\]. Additionally, risk-reducing mastectomy is recommended when known breast cancer--associated gene (*BRCA1*, *BRCA2*, *CDH1*, *PTEN*, *TP53*, and *PALB2*) mutations are identified. Furthermore, the mutations in *ATM*, *BRCA1*, *BRCA2*, *CDH1*, *CHEK2*, *PLAB2*, *PTEN*, *STK11*, and *TP53* suggest that the subsequent screening using breast MRI may be indicated \[[@b24-crt-2017-220]\].

Mutations in the mismatch repair genes (*MLH1*, *MSH2*, *MSH6*, *PMS2*, and *EPCAM*), which cause Lynch syndrome, are often considered the major causes of hereditary EOC, in addition to *BRCA1* and *BRCA2* mutations \[[@b25-crt-2017-220]\]. The identification of these mutations may allow an improved surveillance, leading to the identification of colorectal, endometrial, ovarian, and other cancers in patients with EOC and their relatives \[[@b26-crt-2017-220]\]. An *MSH2*mutation, c.1321dupA (p.Thr441AsnfsTer2), was detected in our study, and the patients had sigmoid colon cancer concomitantly with the family history of stomach cancer. Further large population-based studies are required to establish the frequency of deleterious mutations in these genes.

We detected a non-hereditary breast-ovarian cancer syndrome related gene, *POLE*. The *POLE* gene mutation was reported as a risk factor for the early onset mismatch repairdeficient colorectal cancer \[[@b27-crt-2017-220]\]. According to the NCCN guidelines, enhanced colorectal cancer screening is recommended in patients with a germline mutation in *POLE* gene.

According to the data collected in this study, 78 patients (66.7%) were shown to have 145 VOUSs in 34 genes ([Fig. 3](#f3-crt-2017-220){ref-type="fig"}). Approximately one-third of patients had at least one VOUS, as previously reported in other studies evaluating NGS panels \[[@b4-crt-2017-220],[@b26-crt-2017-220]\]. Most of them will eventually be categorized, most likely as benign, but some will be categorized as deleterious \[[@b12-crt-2017-220],[@b28-crt-2017-220]\]. Until their significance is fully understood, VOUSs should not be used for making clinical decisions.

The application of multi-gene panel testing in the evaluation of cancer susceptibility genes has been rapidly increasing in clinical practice. These multi-gene panel tests can be used for the analysis of not only high-penetrance genes with established clinical utility, but also genes for which clinical validity or significance is currently less evident. The appropriate interpretation of results is important for the development and recommendation of effective strategies for risk management, which may be challenging for clinicians, who often lack genetic training, and for their patients, who should undergo the screening and prevention strategy decision-making process.

In conclusion, here we presented germline mutation data obtained from unselected EOC patients of Asian ethnicity. Overall, 38 out of 117 EOC patients (32.5%) were shown to have 39 germline mutations in eight genes (*BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *MSH2*, *POLE*, *RAD51C*, and *RAD51D*). We identified non-*BRCA1/2* cancer predisposition genes mutation in eight out of 117 patients (6.8%). NGS has a potential to substantially improve the detection rates of a wide spectrum of mutations in ovarian cancer patients compared with the *BRCA1/2* testing alone.
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![Multiple-gene panel testing results. In a patient, multiple mutations were concomitantly identified. EOC, epithelial ovarian cancer; VOUS, variants of uncertain significance. ^a)^Two mutations including *BRCA1* and one non-*BRCA1/2* gene were identified simultaneously in a patient.](crt-2017-220f1){#f1-crt-2017-220}

![Proportion of pathogenic or likely pathogenic mutations and variants of uncertain significance (VOUSs). (A) Multigene panel test results. (B) Proportion and number of pathogenic or likely pathogenic mutations.](crt-2017-220f2){#f2-crt-2017-220}
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###### 

Hereditary cancer predisposition genes included in the multi-gene panel test

  Gene                                   Breast   Ovarian   Colorectal   Endometrial   Pancreatic   Gastric   Prostate   Other
  -------------------------------------- -------- --------- ------------ ------------- ------------ --------- ---------- -------
  *BRCA1, BRCA2*                         O        O         \-           \-            O            \-        O          \-
  *MLH1, MSH2, MSH6, PMS2, EPCAM*        \-       O         O            O             O            O         \-         O
  *STK11*                                O        O         O            O             O            O         \-         O
  *APC, BMPR1A, SMAD4*                   \-       \-        O            \-            O            O         \-         O
  *MUTYH*                                \-       \-        O            \-            \-           \-        \-         O
  *CDKN2A, CDK4*                         \-       \-        \-           \-            O            \-        \-         \-
  *TP53*                                 O        O         O            O             O            O         O          O
  *PTEN*                                 O        \-        O            O             \-           \-        \-         O
  *CDH1*                                 O        \-        O            \-            \-           O         \-         \-
  *PALB2, ATM*                           O        \-        \-           \-            \-           \-        \-         \-
  *CHEK2*                                O        \-        O            \-            O            \-        O          \-
  *NBN*                                  O        \-        \-           \-            \-           \-        O          \-
  *BARD1*                                O        \-        \-           \-            \-           \-        \-         \-
  *BRIP1, RAD51C, RAD51D, RAD50, SLX4*   O        O         \-           \-            \-           \-        \-         \-
  *BLM*                                  \-       \-        \-           \-            \-           \-        \-         O
  *MEN1, RET*                            \-       \-        \-           \-            \-           \-        \-         O
  *MRE11A*                               O        \-        \-           \-            \-           \-        \-         \-
  *POLE*                                 \-       \-        O            \-            \-           \-        \-         \-
  *PRSS1*                                \-       \-        \-           \-            O            \-        \-         \-
  *VHL, WT1*                             \-       \-        \-           \-            \-           \-        \-         O

###### 

Patient characteristics

  Characteristic                  Total (n=117)   Mutation (n=38)^[a)](#tfn1-crt-2017-220){ref-type="table-fn"}^   *BRCA1/2* mutation (n=31)   Non-*BRCA1/2* mutation (n=8)   p-value
  ------------------------------- --------------- ---------------------------------------------------------------- --------------------------- ------------------------------ ---------
  **Age, median (range, yr)**     52 (16-83)      58 (40-76)                                                       56 (45-76)                  54 (40-71)                     0.360
  **Stage**                                                                                                                                                                   
   I                              25 (21.4)       3 (7.9)                                                          1 (3.2)                     2 (25.0)                       0.086
   II                             8 (6.8)         3 (7.9)                                                          3 (9.7)                     0                              
   III                            51 (43.6)       21 (55.3)                                                        18 (58.1)                   4 (50.0)                       
   IV                             33 (28.2)       11 (28.9)                                                        9 (29.0)                    2 (25.0)                       
  **Histology**                                                                                                                                                               
   Serous                         83 (70.9)       33 (86.8)                                                        28 (90.3)                   6 (75.0)                       0.172
   Mucinous                       7 (6.0)         0                                                                0                           0                              
   Endometrioid                   11 (9.4)        1 (2.6)                                                          1 (3.2)                     0                              
   Clear cell                     10 (8.5)        1 (2.6)                                                          0                           1 (12.5)                       
   Mixed                          6 (5.1)         3 (7.9)                                                          2 (6.5)                     1 (12.5)                       
  **Ancestry**                                                                                                                                                                
   Asian                          116 (99.1)      38 (100)                                                         31 (100)                    8 (100)                        \> 0.99
   White/Caucasian                1 (0.9)         0                                                                0                           0                              
  **Family history of cancer**    64 (54.7)       25 (65.8)                                                        21 (67.7)                   4 (50.0)                       0.712
  **Diagnosis at less than 50**   47 (40.2)       10 (26.3)                                                        8 (25.8)                    2 (25.0)                       0.795
  **Concurrent breast cancer**    7 (6.0)         6 (15.8)                                                         6 (19.4)                    0                              0.307

Values are presented as number (%).

Two mutations including *BRCA1* and one non-*BRCA1/2* gene were identified simultaneously in a patient.

###### 

Characteristics of patients with non-*BRCA1/2* mutations

  Case No.   Stage   Histology      Age at diagnosis (yr)   Affected gene   Family history of cancer            Nucleotide change     Amino-acid change dbSNP   Accession No.   Variant effect   Pathogenicity
  ---------- ------- -------------- ----------------------- --------------- ----------------------------------- --------------------- ------------------------- --------------- ---------------- -------------------
  1          IC1     Serous         50                      *RAD51C*        Stomach (mother)                    c.597_603delCACTCTT   p.Phe199LeufsTer38        NM_058216.2     Frameshift       Pathogenic
  2          IIIC    Serous         52                      *RAD51D*        \-                                  c.270_271dupTA        p.Lys91IlefsTer13         NM_002878.3     Frameshift       Pathogenic
  3          IIIC    Seromucinous   56                      *POLE*          Stomach (mother)                    c.6323dupT            p.Cys2109ValfsTer16       NM_006231.2     Frameshift       Pathogenic
  4          IIIC    Serous         57                      *RAD51C*        \-                                  c.597_603delCACTCTT   p.Phe199LeufsTer38        NM_058216.2     Frameshift       Pathogenic
  5          IIIC    Serous         58                      *RAD51D*        \-                                  c.904-2A\>T           \-                        NM_002878.3     Splicing         Likely pathogenic
  6          IVB     Serous         71                      BRIP1           \-                                  c.1776G\>A            p.Trp592Ter               NM_032043.2     Nonsense         Pathogenic
  7          IC3     Clear          49                      *MSH2*          Stomach (father), colon (brother)   c.1321dupA            p.Thr441AsnfsTer2         NM_000251.2     Frameshift       Pathogenic
  8          IVB     Serous         40                      *CHEK2*         Colon (father)                      c.1555C\>T            p.Arg519Ter               NM_007194.3     Nonsense         Pathogenic
